Coherus biosciences reports first quarter 2025 financial results and provides business update

– strategic transformation to innovative oncology completed in q2 2025 – – positive chs-114 (anti-ccr8 antibody) phase 1b dose expansion study data in patients with head and neck cancer presented at 2025 aacr annual meeting – – additional chs-114 phase 1b studies in 2l gastric cancer and 2l hnscc ongoing – – enrollment ongoing in the phase 2 randomized trial of casdozokitug/toripalimab/bevacizumab in 1l hcc, with first data readout expected in 1h 2026 – – loqtorzi net revenue was $7.3 million and udenyca net revenue, now reflected in discontinued operations, was $31.5 million in q1 2025  – – conference call today at 5:00 p.m. eastern time – redwood city, calif.
CHSCL Ratings Summary
CHSCL Quant Ranking